% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Coenen:7089,
      author       = {Coenen, H. H. and Elsinga, P.H. and Iwata, R. and Kilbourn,
                      M.R. and Pillai, M.R.A. and Rajan, M.G.R. and Wagner, H.N.
                      and Zaknun, J.},
      title        = {{F}luorine-18 radiopharmaceuticals (beyond [18{F}]{FDG})
                      for use in oncology and neurosciences},
      journal      = {Nuclear medicine and biology},
      volume       = {37},
      issn         = {1872-9614},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {PreJuSER-7089},
      pages        = {727 - 740},
      year         = {2010},
      note         = {The Consultants acknowledge the IAEA for its interest and
                      activities in this important field. The authors from the
                      IAEA (MRAP and JJZ) thank Dr. M. Haji-Saeid, Head,
                      Industrial Applications and Chemistry Section, Dr. M. Dondi,
                      Head, Nuclear Medicine Section, and Dr N. Ramamoorthy,
                      Director-NAPC, International Atomic Energy Agency for their
                      support and encouragement.},
      comment      = {Report of an IAEA Consultants Group Meeting},
      booktitle     = {Report of an IAEA Consultants Group
                       Meeting},
      abstract     = {Positron emission tomography (PET) is a rapidly expanding
                      clinical modality worldwide thanks to the availability of
                      compact medical cyclotrons and automated chemistry for the
                      production of radiopharmaceuticals. There is an
                      armamentarium of fluorine-18 ((18)F) tracers that can be
                      used for PET studies in the fields of oncology and
                      neurosciences. However, most of the (18)F-tracers other than
                      2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than
                      optimum human use and there is considerable scope to bring
                      potentially useful (18)F-tracers to clinical investigation
                      stage. The International Atomic Energy Agency (IAEA)
                      convened a consultants' group meeting to review the current
                      status of (18)F-based radiotracers and to suggest means for
                      accelerating their use for diagnostic applications. The
                      consultants reviewed the developments including the
                      synthetic approaches for the preparation of (18)F-tracers
                      for oncology and neurosciences. A selection of three groups
                      of (18)F-tracers that are useful either in oncology or in
                      neurosciences was done based on well-defined criteria such
                      as application, lack of toxicity, availability of precursors
                      and ease of synthesis. Based on the recommendations of the
                      consultants' group meeting, IAEA started a coordinated
                      research project on "Development of (18)F
                      radiopharmaceuticals (beyond [(18)F]FDG) for use in oncology
                      and neurosciences" in which 14 countries are participating
                      in a 3-year collaborative program. The outcomes of the
                      coordinated research project are expected to catalyze the
                      wider application of several more (18)F-radiopharmaceuticals
                      beyond FDG for diagnostic applications in oncology and
                      neurosciences.},
      keywords     = {Animals / Fluorodeoxyglucose F18: diagnostic use / Humans /
                      Neoplasms: radionuclide imaging / Nervous System Diseases:
                      radionuclide imaging / Radiopharmaceuticals: diagnostic use
                      / Radiopharmaceuticals (NLM Chemicals) / Fluorodeoxyglucose
                      F18 (NLM Chemicals) / J (WoSType)},
      cin          = {INM-5 / JARA-BRAIN},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-5-20090406 / $I:(DE-82)080010_20140620$},
      pnm          = {Funktion und Dysfunktion des Nervensystems (FUEK409) /
                      89572 - (Dys-)function and Plasticity (POF2-89572)},
      pid          = {G:(DE-Juel1)FUEK409 / G:(DE-HGF)POF2-89572},
      shelfmark    = {Radiology, Nuclear Medicine $\&$ Medical Imaging},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:20870148},
      UT           = {WOS:000282803500001},
      doi          = {10.1016/j.nucmedbio.2010.04.185},
      url          = {https://juser.fz-juelich.de/record/7089},
}